In a significant stride for diagnostic medicine, Minnesota-based Zepto Life Technology has been awarded a multi-year contract from the U.S. National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID). The contract, which provides an initial infusion of $1.9 million with the potential to reach $8.9 million upon the successful attainment of specified development milestones, is earmarked for the advancement of Zepto’s integrated molecular diagnostic system—a platform designed to transform the clinical management of invasive fungal infections.
This funding boost arrives on the heels of a major regulatory milestone achieved in June 2026, when the U.S. Food and Drug Administration (FDA) granted "breakthrough device" status to Zepto’s FungiFlex mould panel. As the medical community grapples with the rising complexity of fungal pathogens, this public-private partnership signals a concerted effort to move beyond the limitations of traditional, time-consuming culture-based diagnostics.
The Core Innovation: FungiFlex and GMR Technology
At the heart of Zepto’s technological arsenal is its proprietary Giant Magnetoresistance (GMR) biosensor technology. Unlike traditional diagnostic methods that rely on long-duration culture incubation—which can take days or weeks—the FungiFlex system offers a rapid, highly sensitive liquid biopsy approach.
The platform is designed to detect and identify cell-free DNA (cfDNA) directly from plasma samples. This methodological shift is critical; by eliminating the need for invasive tissue biopsies or waiting for fungal growth in culture, clinicians can initiate targeted antifungal therapy significantly earlier in the disease course. Currently, FungiFlex is accessible via Zepto’s CLIA-certified reference laboratory as a laboratory-developed test (LDT).
The panel is highly comprehensive, capable of identifying 14 clinically significant mould pathogens, including:
- Aspergillus (a leading cause of invasive aspergillosis)
- Mucorales (responsible for mucormycosis)
- Fusarium
- Scedosporium/Lomentospora
By targeting these specific pathogens, the system provides a robust shield against the most common and deadliest forms of invasive mould infections, particularly in immunocompromised patient populations.
Chronology of Development: From Concept to Breakthrough
The trajectory of Zepto’s FungiFlex panel reflects a rapid acceleration in diagnostic innovation over the last two years:
- Early Development Phase: Zepto focuses on perfecting the GMR biosensor technology, aiming to create a platform that combines the sensitivity of molecular testing with the portability and speed required for a hospital setting.
- CLIA-Certified Launch: Zepto establishes its own reference laboratory, allowing the company to offer the FungiFlex panel as an LDT to medical institutions, thereby generating clinical evidence and physician feedback in real-world scenarios.
- June 2026 (FDA Recognition): The FDA grants the FungiFlex mould panel "breakthrough device" designation. This status is reserved for technologies that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human diseases, signaling that the device holds significant promise for unmet clinical needs.
- August 2026 (NIAID Contract): The NIAID awards a contract worth up to $8.9 million to support the engineering, manufacturing, and clinical validation of the FungiFlex system. This marks the transition of the technology from a niche reference lab service to a potentially standardized, widespread hospital diagnostic tool.
The Clinical Imperative: Why Rapid Diagnosis Matters
The clinical urgency surrounding this technology is underscored by data from the U.S. Centers for Disease Control and Prevention (CDC). Invasive mould infections are notoriously difficult to diagnose, often presenting with non-specific symptoms that overlap with bacterial or viral infections.
The Cost of Delay
The CDC notes that misdiagnosis or delayed diagnosis is a frequent occurrence in clinical settings. This delay is not merely a bureaucratic issue; it has profound medical and economic consequences. In cases of invasive fungal disease, every hour counts. Delayed treatment is directly correlated with higher mortality rates, prolonged intensive care unit (ICU) stays, and increased healthcare expenditure.
With an estimated population-based prevalence of 15 to 18 cases per 100,000 people in the United States, the burden of these infections is substantial. For high-risk patients—such as those undergoing chemotherapy, organ transplants, or suffering from chronic lung disease—the diagnostic speed provided by a liquid biopsy could mean the difference between recovery and systemic organ failure.
Official Perspectives: CEO Hannah Zhang on the Future of Diagnostics
The infusion of NIAID funding is not just a financial victory; it is a validation of Zepto’s long-term vision. CEO Hannah Zhang views this contract as the catalyst needed to transition FungiFlex from a central lab service to a point-of-care solution.
"Today, FungiFlex is available through our CLIA reference laboratory, but we’ve always been building toward something bigger," Zhang stated following the announcement. "This award helps us advance Zepto’s technology as a deployable liquid biopsy platform for infectious disease and bring that capability directly into hospital microbiology laboratories."
Zhang emphasizes that the ultimate goal is decentralization. By bringing the diagnostic capability "in-house" to hospitals, Zepto intends to shrink the diagnostic window. "That means getting clinicians actionable answers closer to the moment they first suspect an infection," she added. This "time-to-action" metric is the gold standard by which the efficacy of the new system will be judged during upcoming clinical trials.
Strategic Implications: Engineering a New Standard of Care
The $8.9 million contract is structured in stages, with the initial $1.9 million serving as the foundation for intensive research and development. The remaining funding is contingent upon the achievement of key milestones, which include:
- Engineering Refinement: Enhancing the robustness of the GMR biosensor system to ensure it can withstand the rigors of high-throughput hospital laboratory environments.
- Manufacturing Scalability: Developing the infrastructure required to produce the FungiFlex panel components at a scale that meets national demand.
- Clinical Validation: Executing a rigorous, multi-site clinical study. This data will be the cornerstone of Zepto’s formal submission to the FDA for de novo clearance or 510(k) approval, shifting the product from an LDT to a fully cleared diagnostic device.
This strategic roadmap is indicative of a broader trend in the NIH’s funding strategy. The agency has increasingly prioritized the development of rapid, accessible, and high-precision diagnostic tools to combat infectious threats. This is clearly evidenced by the NIH’s recent investment in the Gladstone Institutes—which received $10 million in June 2026 to establish the Center for PhAIge Therapy. By funding both rapid detection (Zepto) and innovative treatment (Gladstone), the NIH is tackling the infectious disease crisis from both ends of the spectrum.
The Landscape of Competitive Diagnostics
While other diagnostic platforms exist, few combine the specific advantages of Zepto’s GMR technology with the liquid biopsy approach. Traditional PCR-based methods often require extensive sample preparation and can be prone to contamination. Culture-based methods, while traditional, lack the necessary speed for acute infections.
By positioning FungiFlex in the "liquid biopsy" space, Zepto is essentially creating a new sub-category of fungal diagnostics. If the clinical trials prove successful, the ability to monitor fungal cfDNA in real-time could also open the door to "theranostics"—the practice of using diagnostic testing to monitor a patient’s response to treatment and adjusting the dosage of antifungal medication in real-time, further reducing toxicity and improving patient outcomes.
Conclusion: A New Era for Microbiology
The partnership between Zepto Life Technology and the NIAID represents a convergence of cutting-edge biosensor engineering and urgent public health necessity. As the company moves toward its clinical trial milestones, the medical community will be watching closely.
If Zepto succeeds, the standard of care for invasive mould infections could shift from the "wait-and-see" approach of traditional microbiology to a proactive, precision-medicine model. For the clinicians on the front lines and the patients facing these life-threatening infections, this development is a promising beacon, offering the potential for rapid, accurate, and actionable data at the bedside.
As the industry looks toward the next phase of development, the success of the FungiFlex system will likely be measured by its ability to seamlessly integrate into the hospital ecosystem. With the backing of the NIAID and the momentum of its FDA breakthrough designation, Zepto is well-positioned to turn the tide against some of the most persistent and lethal pathogens in the clinical repertoire.
About the Author
